Codexis Inc. (CDXS) Trading Down 4.9%
Shares of Codexis Inc. (NASDAQ:CDXS) fell 4.9% on Wednesday . The stock traded as low as $4.07 and last traded at $4.07, with a volume of 73,117 shares changing hands. The stock had previously closed at $4.28.
Several research firms have weighed in on CDXS. Zacks Investment Research cut Codexis from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. HC Wainwright reaffirmed a “buy” rating on shares of Codexis in a report on Tuesday, May 10th.
The stock’s market cap is $166.82 million. The company’s 50-day moving average is $4.06 and its 200 day moving average is $3.79.
Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Monday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. The company had revenue of $8 million for the quarter, compared to the consensus estimate of $7.49 million. During the same period in the prior year, the firm posted ($0.07) EPS. The business’s revenue for the quarter was up 17.6% on a year-over-year basis. Equities research analysts anticipate that Codexis Inc. will post ($0.25) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Codexis stock. EAM Investors LLC increased its stake in shares of Codexis Inc. (NASDAQ:CDXS) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 407,255 shares of the company’s stock after buying an additional 1,604 shares during the period. EAM Investors LLC owned about 1.01% of Codexis worth $1,723,000 as of its most recent SEC filing.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.